Atrial Natriuretic Peptide (ANP), rat: Molecular Mechanisms and Research Benchmarks

Executive Summary: Atrial Natriuretic Peptide (ANP), rat is a 28-amino acid peptide hormone with a molecular formula C₄₉H₈₄N₂₀O₁₅S and a molecular weight of 1225.38 g/mol, synthesized in atrial myocytes in response to atrial distension and neurohormonal stimuli (APExBIO, A1009). ANP acts as a potent vasodilator, maintaining sodium, water, and adipose tissue homeostasis, and lowering systemic blood pressure via natriuretic and diuretic effects (bnp1-32.com). The A1009 reagent exhibits >95% purity by HPLC/mass spectrometry and is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, but insoluble in ethanol. It is widely used in cardiovascular and renal research workflows, with validated protocols for acute and chronic studies in rat models (endothelin-1.com). APExBIO’s ANP supports reproducible investigation of natriuresis mechanisms, blood pressure regulation, and adipose tissue metabolism, with storage and handling rigorously defined (stored at -20°C, used promptly after dissolution).

Biological Rationale

Atrial Natriuretic Peptide (ANP), rat is endogenously produced by atrial myocytes. Its synthesis and secretion are triggered by atrial stretch, angiotensin II, endothelin, and sympathetic nervous system activation (APExBIO). ANP is central to cardiovascular homeostasis, acting as a counter-regulatory hormone to the renin-angiotensin-aldosterone system (RAAS). It promotes vasodilation, natriuresis (sodium excretion), and diuresis (water excretion), thereby reducing blood pressure and extracellular fluid volume. Additionally, ANP modulates adipose tissue metabolism by promoting lipolysis and influencing adiponectin levels, integrating cardiovascular and metabolic regulation. In rat models, ANP is a critical experimental tool for dissecting these physiological processes and their pathophysiological alterations in hypertension, heart failure, and metabolic syndrome (big-endothelin-1.com).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP, rat functions primarily via binding to natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylyl cyclase receptor. This interaction elevates intracellular cyclic guanosine monophosphate (cGMP) levels, activating protein kinase G (PKG) pathways. The result is smooth muscle relaxation (vasodilation), increased glomerular filtration rate (GFR), and inhibition of sodium reabsorption in the renal collecting ducts. ANP also suppresses renin and aldosterone secretion, further reducing sodium retention. In adipose tissue, ANP stimulates lipolysis and modulates adiponectin secretion, intersecting with metabolic regulatory pathways. Recent evidence suggests that ANP and adiponectin pathways may interact, influencing neuroinflammatory and oxidative stress responses in rat models (Zhang et al., 2022).

Evidence & Benchmarks

• ANP, rat (APExBIO A1009) is >95.92% pure by HPLC and mass spectrometry under standard laboratory conditions (APExBIO product page).
• Acute intravenous administration of ANP in rats produces rapid vasodilation and natriuresis within 5–15 minutes at doses of 1–10 μg/kg (endothelin-1.com).
• ANP downregulates renin and aldosterone secretion, reducing sodium reabsorption and lowering blood pressure in hypertensive rat models (big-endothelin-1.com).
• In metabolic studies, ANP enhances adiponectin release, contributing to improved lipid metabolism and attenuated neuroinflammatory markers in rats (Zhang et al., 2022).
• ANP is insoluble in ethanol but dissolves at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, supporting diverse experimental protocols (APExBIO).

Applications, Limits & Misconceptions

ANP, rat is employed in cardiovascular, renal, and metabolic research:

• Blood pressure regulation studies via acute and chronic infusion.
• Natriuresis mechanism studies in renal physiology.
• Adipose tissue metabolism and neuroimmune modulation research.
• Therapeutic target validation in hypertension and heart failure models.

This article expands on prior internal content such as "Atrial Natriuretic Peptide: Applied Workflows for Cardiov..." by providing specific benchmarks for purity, solubility, and validated experimental outcomes in rat models, and extends the mechanistic detail described in "Atrial Natriuretic Peptide (ANP), rat: Mechanism, Evidence..." by integrating recent evidence on ANP-adiponectin cross-talk. For a comprehensive protocol perspective, see "Atrial Natriuretic Peptide: Applied Protocols for Cardiov...", which this dossier updates with latest purity metrics and solubility data.

Common Pitfalls or Misconceptions

• ANP, rat is not effective in non-mammalian species or in cell-free biochemical systems lacking natriuretic peptide receptors.
• Long-term storage of dissolved ANP solutions at room temperature or above -20°C leads to peptide degradation and loss of activity.
• ANP is insoluble in ethanol, which can precipitate or inactivate the peptide if used as solvent.
• Blood pressure changes induced by ANP are dose-dependent and reversible; chronic overstimulation can downregulate NPR-A receptors, limiting efficacy.
• ANP does not substitute for downstream effectors such as cGMP analogs in mechanistic studies.

Workflow Integration & Parameters

The A1009 reagent from APExBIO is supplied as a solid and should be stored at -20°C. Dissolution should be performed in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL), and solutions should be used promptly to avoid degradation (Atrial Natriuretic Peptide (ANP), rat). Standard dosing regimens in rats range from 1–10 μg/kg for acute studies; chronic administration protocols require daily preparation of fresh solution. Analytical confirmation of integrity (HPLC, mass spectrometry) is recommended for high-precision applications. ANP is validated in cardiovascular, renal, and metabolic workflows, with compatibility for combinatorial studies involving adiponectin and TLR4/NF-κB pathway modulators (Zhang et al., 2022).

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat remains an essential molecular tool for dissecting mechanisms of blood pressure homeostasis, natriuresis, and metabolic regulation in preclinical research. APExBIO’s A1009 reagent sets a benchmark for purity, solubility, and reproducibility in experimental design. Future studies are poised to leverage ANP’s interactions with adipokines and neuroimmune pathways for translational advances in cardiovascular and metabolic disease models.